Related News
Home » Business » Manufacturing
Glaxo seeks 'bolt-on' links for new drugs
By Trista Kelley |
January 10, 2009, Saturday
|
Print Edition
Print Edition
GLAXOSMITHKLINE Plc, Europe's largest drug maker, will boost its reliance on acquisitions and licensing deals to bring new medicines to the market, Chief Executive Officer Andrew Witty said in an interview.
The London-based company has 30 drugs in the final stage of testing needed before approval and plans to release about five new products a year, Witty, 44, told Bloomberg News in New York on Thursday. Glaxo will sustain drug development by seeking smaller, "bolt-on" alliances and takeovers, or deals valued from about US$50 million to the "low billions," he said.
"I would feel very comfortable if five or six years down the road half of our drug approvals came from products which weren't originally discovered in a GSK laboratory," Witty said. "Now, that number is more like 25 percent to 30 percent."
Witty, who took over as CEO last May, said Glaxo will expand into emerging markets and over-the-counter products, mostly through acquisitions and licensing agreements. The drug maker will also focus on developing vaccines.
The London-based company has 30 drugs in the final stage of testing needed before approval and plans to release about five new products a year, Witty, 44, told Bloomberg News in New York on Thursday. Glaxo will sustain drug development by seeking smaller, "bolt-on" alliances and takeovers, or deals valued from about US$50 million to the "low billions," he said.
"I would feel very comfortable if five or six years down the road half of our drug approvals came from products which weren't originally discovered in a GSK laboratory," Witty said. "Now, that number is more like 25 percent to 30 percent."
Witty, who took over as CEO last May, said Glaxo will expand into emerging markets and over-the-counter products, mostly through acquisitions and licensing agreements. The drug maker will also focus on developing vaccines.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
